| Identification | Back Directory | [Name]
1-Naphthalenesulfonic acid, 5-(dimethylamino)-, 2,3-dihydro-2-oxo-3-(2-phenylethyl)-4-benzoxazolyl ester | [CAS]
2241674-94-0 | [Synonyms]
iNOs-IN-3
1-Naphthalenesulfonic acid, 5-(dimethylamino)-, 2,3-dihydro-2-oxo-3-(2-phenylethyl)-4-benzoxazolyl ester | [Molecular Formula]
C27H24N2O5S | [MOL File]
2241674-94-0.mol | [Molecular Weight]
488.55 |
| Hazard Information | Back Directory | [Uses]
iNOs-IN-3 (Compound 2d) is an orally active nitric oxide synthase (iNOS) inhibitor (IC50=3.342 μM). iNOs-IN-3 shows anti-inflammatory activity and can be used in LPS-induced acute lung injury (ALI) research[1]. | [in vivo]
iNOs-IN-3 (oral administration; 12.5 mg/kg; once) treatment shows anti-inflammatory activity against xylene-induced ear edema in mice[1].
iNOs-IN-3 (oral administration; 3.125 mg/kg, 6.25 mg/kg, 12.5 mg/kg; once) protects against LPS-induced acute lung injury[1]. | Animal Model: | Xylene-induced mice[1] | | Dosage: | 12.5 mg/kg | | Administration: | Oral administration; 12.5 mg/kg; once | | Result: | Showed better activity than the positive control. |
| Animal Model: | LPS-induced acute lung injury (ALI) mice[1] | | Dosage: | 3.125 mg/kg, 6.25 mg/kg, 12.5 mg/kg | | Administration: | Oral administration; 3.125 mg/kg, 6.25 mg/kg, 12.5 mg/kg; once | | Result: | Attenuated the pathological lesions dose-dependently, such as decreased inflammatory infiltration and pulmonary congestion. Inhibited LPS-induced lung edema dose-dependently.
|
| [References]
[1] Li Tang, et al. Design and synthesis of new disubstituted benzoxazolone derivatives that act as iNOS inhibitors with potent anti-inflammatory activity against LPS-induced acute lung injury (ALI). Bioorg Med Chem. 2020 Nov 1;28(21):115733. DOI:10.1016/j.bmc.2020.115733 |
|
|